Transaction Valuation*
|
Amount of Filing Fee**
|
$6,579,204,583
|
$753,976.85
|
*
|
Estimated for purposes of calculating the filing fee only. This amount assumes the purchase of all 121,439,286 shares of common stock of Illumina, Inc. outstanding as of October 15, 2011, all 10,420,000 shares of common stock of Illumina subject to issuance pursuant to options outstanding as of October 2, 2011, all 3,124,000 shares of common stock of Illumina subject to issuance pursuant to outstanding restricted stock units as of October 2, 2011 and approximately 12,864,000 shares of common stock of Illumina subject to issuance upon conversion of Illumina’s outstanding convertible notes. The number of outstanding shares, options, and restricted stock units is contained in Illumina’s Quarterly Report on Form 10-Q for the quarter ended October 2, 2011. The numbers of shares subject to issuance upon conversion of Illumina’s outstanding convertible notes is based on filings by Illumina with the Securities and Exchange Commission.
|
**
|
The amount of the filing fee is calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, by multiplying the transaction valuation by .00011460.
|
R
|
Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
Amount Previously Paid:
|
$753,976.85
|
Filing Party:
|
CKH Acquisition Corporation
|
|
Form or Registration No.:
|
SC TO-T
|
Date Filed:
|
January 27, 2012
|
£
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
R
|
third-party tender offer subject to Rule 14d-1.
|
£
|
issuer tender offer subject to Rule 13e-4.
|
£
|
going-private transaction subject to Rule 13e-3.
|
£
|
amendment to Schedule 13D under Rule 13d-2.
|
Exhibit (a)(5)(iv)
|
Press Release issued by Roche Holding Ltd, dated January 31, 2012.
|
CKH ACQUISITION CORPORATION
|
|||
By: | /s/ Bruce Resnick | ||
Name: | Bruce Resnick | ||
Title: | President |
ROCHE HOLDING LTD
|
|||
By: | /s/ Dr. Gottlieb Keller | ||
Name: | Dr. Gottlieb Keller | ||
Title: | Authorized Signatory |
By: | /s/ Dr. Beat Kraehenmann | ||
Name: | Dr. Beat Kraehenmann | ||
Title: | Authorized Signatory |
Exhibit No.
|
Description
|
(a)(1)(i)
|
Offer to Purchase dated January 27, 2012.*
|
(a)(1)(ii)
|
Letter of Transmittal (including the Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9).*
|
(a)(1)(iii)
|
Notice of Guaranteed Delivery.*
|
(a)(1)(iv)
|
Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
|
(a)(1)(v)
|
Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
|
(a)(1)(vi)
|
Summary Advertisement dated January 27, 2012.*
|
(a)(5)(i)
|
Press Release issued by Roche Holding Ltd, dated January 27, 2012.*
|
(a)(5)(ii)
|
Roche Memorandum to Global Sales Teams, dated January 27, 2012.*
|
(a)(5)(iii)
|
Transcript of Video Message to Roche Employees, dated January 30, 2012.*
|
(a)(5)(iv)
|
Press Release issued by Roche Holding Ltd, dated January 31, 2012.
|
(b)
|
Not applicable.
|
(c)
|
Not applicable.
|
(d)
|
Not applicable.
|
(f)
|
Not applicable.
|
(g)
|
Not applicable.
|
(h)
|
Not applicable.
|